Ziarco, Novartis deal

Novartis will acquire Ziarco for undisclosed financial terms. The deal gives the pharma ZPL-389, an oral histamine H4 receptor (HRH4; H4) antagonist. Ziarco previously said ZPL-389 missed the primary ...